Celebrex Switches Create Approximately 7% of Scripts For Merck Vioxx
Switches from Celebrex to Vioxx accounted for approximately 7% of prescriptions for Merck's COX-2 inhibitor during November.
You may also be interested in...
Pfizer/Searle's Celebrex ended 1999 with a total of 16.6 mil. prescriptions following a January 1999 launch, while Merck's Vioxx had 4.6 mil. prescriptions for the year after its May launch, according to IMS Health data
Merck is looking to move patients out of the over-the-counter analgesic market to the prescription COX-2 inhibitor Vioxx, Merck Human Health-The Americas President David Anstice said at Merck's annual business briefing Dec. 9 in Whitehouse Station, N.J.
Searle has promised its pharmaceutical buyers that it will not raise prices on any of its products before March 1, 2000.